Thursday, January 18, 2018 -- Z-CAN was designed as a short-term response for rapid implementation of reversible contraceptive services in a complex emergency setting in Puerto Rico and has served more than 21 000 women. This model could be replicated or adapted as part of future emergency preparedness and response efforts.
Wednesday, January 17, 2018 -- In what looks like a typical doctor’s office, Gary Newcomer, 26, waited to have his blood drawn for the last time as a participant in a trial for a Zika virus vaccine. Newcomer has visited Saint Louis University’s Center for Vaccine Development 16 times since November 2016. But a cut in federal funding is bringing a halt to the trial before a vaccine can be developed.
Tuesday, January 16, 2018 -- Lisa Schnirring | News Editor | CIDRAP NewsJan 16, 2018One study reaffirms the Zika-microcephaly link; the other spotlights economic factors.
Wednesday, January 10, 2018 -- Inhibition of the endoplasmic reticulum stress pathway may hold the key to Zika virus–associated microcephaly treatment.
Friday, January 05, 2018 -- Zika virus (ZIKV) infection during pregnancy is associated with adverse fetal outcomes, including microcephaly, growth restriction, and fetal demise. Type I interferons (IFNs) are essential for host resistance against ZIKV, and IFN-α/β receptor (IFNAR)–deficient mice are highly susceptible to ZIKV infection. Severe fetal growth restriction with placental damage and fetal resorption is observed after ZIKV infection of type I IFN receptor knockout (Ifnar1–/–) dams mated with wild-type sires, resulting in fetuses with functional type I IFN signaling. The role of type I IFNs in limiting or mediating ZIKV disease within this congenital infection model remains unknown. In this study, we challenged Ifnar1–/– dams mated with Ifnar1+/– sires with ZIKV. This breeding scheme enabled us to examine pregnant dams that
Tuesday, January 02, 2018 -- In Aedes aegypti females, the ammonia released during blood meal digestion is partially metabolized to facilitate the disposal of excess nitrogen. In this study, we used low- and high-resolution liquid chromatography-mass spectrometry (LC/MS) techniques to investigate the role of glucose during ammonia detoxification. Mosquitoes were fed a blood meal supplemented with [1,2-13C2]glucose, and downstream metabolites were measured for 24 h. Quantification of [13C] amino acids in the entire mosquito body was conducted without sample derivatization using selected reaction monitoring of mass transitions that are indicative of the structural position of [13C] atom incorporation. Identification of unlabeled and [13C] isotopologs of 43 compounds, including amino acids, amino acid derivatives, and organic acids, was performed by high-resolution LC/MS techniques. Blood-fed mosquitoes
Tuesday, December 19, 2017 -- by Bryson Alberto Ndenga, Francis Maluki Mutuku, Harun Njenga Ngugi, Joel Omari Mbakaya, Peter Aswani, Peter Siema Musunzaji, John Vulule, Dunstan Mukoko, Uriel Kitron, Angelle Desiree LaBeaud Aedes aegypti is the main vector for yellow fever, dengue, chikungunya and Zika viruses. Recent outbreaks of dengue and chikungunya have been reported in Kenya. Presence and abundance of this vector is associated with the risk for the occurrence and transmission of these diseases. This study aimed to characterize the presence and abundance of Ae. aegypti adult mosquitoes from rural and urban sites in western and coastal regions of Kenya. Presence and abundance of Ae. aegypti adult mosquitoes were determined indoors and outdoors in two western (urban Kisumu and rural Chulaimbo) and
Friday, December 15, 2017 -- Most children born with microcephaly – small head size for age – and evidence of congenital Zika virus infection face severe health and developmental challenges at ages 19-24 months, according to results from a new investigation led by the Centers for Disease Control and Prevention (CDC) in collaboration with the State Health Secretariat of Paraíba and the […] The post Congenital Zika: Children face severe health and developmental challenges over time appeared first on Outbreak News Today.
Thursday, December 14, 2017 -- A baby born with microcephaly caused by Zika virus in a rehabilitation center in Recife, Brazil, last year. The most severely affected babies have little language or mobility and will likely require a lifetime of care, a new study shows.
Wednesday, December 13, 2017 -- Jim Wappes | Editorial Director | CIDRAP NewsDec 13, 2017No link was found between microcephaly and a key insecticide—or vaccines.
Wednesday, December 13, 2017 -- An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector–based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as
Tuesday, December 12, 2017 -- An alternative animal model that mimics key features of the Zika virus infection, including its lingering presence in bodily fluids, has been developed at Texas Biomedical Research Institute in San Antonio.
Monday, December 11, 2017 -- The association between microcephaly and congenital Zika virus infection was confirmed. We provide evidence of the absence of an effect of other potential factors, such as exposure to pyriproxyfen or vaccines (tetanus, diphtheria, and acellular pertussis, measles and rubella, or measles, mumps, and rubella) during pregnancy, confirming the findings of an ecological study of pyriproxyfen in Pernambuco and previous studies on the safety of Tdap vaccine administration during pregnancy.
Thursday, December 07, 2017 -- Results from two Phase 1 clinical trials show an experimental Zika vaccine is safe and induces an immune response in healthy adults.
Tuesday, December 05, 2017 -- The results of 3 phase 1 clinical trials have shown that an investigational Zika purified inactivated virus vaccine was well-tolerated and induced an immune response in adult participants.
Monday, December 04, 2017 -- In response to the urgent need for a vaccine to prevent congenital syndromes associated with Zika virus, the scientific community has responded swiftly. Several vaccine technologies are in development. In The Lancet, Kayvon Modjarrad and colleagues1 and Martin R Gaudinski and colleagues2 report results of phase 1 clinical trials of candidate Zika vaccines. It has been less than 2 years since the association between Zika virus infection and microcephaly was established in Recife, Brazil,3,4 and to have multiple promising vaccine candidates in so short a time is impressive.
Monday, December 04, 2017 -- VRC5283 was well tolerated and has advanced to phase 2 efficacy testing.
Friday, December 01, 2017 -- BACKGROUND AND OBJECTIVE: In July 2016, local transmission of Zika virus (ZIKV) was announced in Miami-Dade County, Florida. In this report, we describe the epidemiology of pediatric ZIKV infections in locally acquired and travel-associated cases. METHODS: All children aged 1 to 17 years tested for ZIKV between October 1, 2015, and March 29, 2017, were included. SAS 9.4 was used to analyze age, sex, race and/or ethnicity, origin of exposure, onset date, affiliation with a household cluster, clinical symptoms, hospitalizations, viremia, viruria, and antibody detection in specimens. RESULTS: Among 478 confirmed ZIKV cases in Miami-Dade County, 33 (6.9%) occurred in children (1–17 years). Twenty-seven (82.3%) cases were travel-associated. The median age of a pediatric Zika case patient was 11
Wednesday, November 29, 2017 -- Japan's Takeda Pharmaceutical has started a phase 1 clinical trial of its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate, TAK-426.
Tuesday, November 28, 2017 -- LONDON (Reuters) - Japan's Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquito-borne Zika virus, with the start of a clinical trial program backed by the U.S. government.